GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis
- First Posted Date
- 2008-06-11
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT00694980
A Study of Pulmozyme® (Dornase Alpha) in 3- to 5-Year-Old Patients With Cystic Fibrosis
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT00680316
A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2008-05-16
- Last Posted Date
- 2017-03-31
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT00679211
A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
Phase 2
Completed
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- First Posted Date
- 2008-05-13
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT00676715
- Locations
- 🇺🇸
Phoenix Neurological Associates Ltd, Phoenix, Arizona, United States
🇧🇬CCB Medical institute, Ministry of Interior Sofia; CLINIC OF NEUROLOGY, Sofia, Bulgaria
🇺🇸MS Center of Vero Beach, Vero Beach, Florida, United States
A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy
Phase 3
Terminated
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2020-12-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 314
- Registration Number
- NCT00673920
A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer
Phase 1
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT00671372
A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp
- First Posted Date
- 2008-04-30
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 89
- Registration Number
- NCT00669214
An Observational Study of TNKase in Patients Enrolled in the National Registry of Myocardial Infarction 4 and 5 (POST)
Completed
- Conditions
- Acute Myocardial Infarction
- First Posted Date
- 2008-04-29
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 253668
- Registration Number
- NCT00669045
A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2008-04-23
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT00664898
Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1058
- Registration Number
- NCT00662038
- Locations
- 🇺🇸
Genentech, Inc., South San Francisco, California, United States
© Copyright 2025. All Rights Reserved by MedPath